Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax and Azacitidine in the Post-Transplant Setting for AML and Leukemia
NCT04128501Phase 2Active, not recruiting
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2020
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of venetoclax, azacitidine in acute myeloid leukemia (AML), Acute Bilineal Leukemia (ABL), Acute Biphenotypic Leukemia (BAL), t-cell acute lymphoblastic leukemia (T-ALL), sponsored by University of Texas MD Anderson Cancer Center. Started May 2020; status: active, not recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
acute myeloid leukemia (AML)Acute Bilineal Leukemia (ABL)Acute Biphenotypic Leukemia (BAL)t-cell acute lymphoblastic leukemia (T-ALL)
Beyond the preview
Go deeper on NCT04128501.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04128501.